Sam Brusco, Associate Editor02.07.24
Insulet has earned CE mark clearance to add compatibility of Abbott’s FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor to its Omnipod 5 automated insulin pump for type 1 diabetes patients aged two years and older.
Omnipod 5 is the first tubeless, hybrid closed-loop system—known as automated insulin delivery—with EU approval and integrated with two CGM sensor brands, Dexcom and Abbott FreeStyle Libre. The system is comprised of the tubeless Pod, SmartAdjust software, and a controller with a Smartbolus calculator.
SmartAdjust receives a CGM value and trend, then predicts where glucose levels will be an hour later. The system corrects every five minutes based on desired and customized glucose target.
The company anticipates the integrated technology to debut in the UK and Netherlands in phased launch in H1 2024.
“The addition of the Abbott FreeStyle Libre 2 Plus sensor to our CGM compatibility expands accessibility of Omnipod 5, which has been a priority for Insulet since the system launched in 2022,” said Patrick Crannell, Insulet’s senior VP and international GM. “We are excited to have achieved this key milestone, which allows us to bring Omnipod 5 and choice of CGM to more people with diabetes.”
The company released The OmniPod 5 AID integrated with the Dexcom G6 CGM in Germany in October 2023.
Omnipod 5 is the first tubeless, hybrid closed-loop system—known as automated insulin delivery—with EU approval and integrated with two CGM sensor brands, Dexcom and Abbott FreeStyle Libre. The system is comprised of the tubeless Pod, SmartAdjust software, and a controller with a Smartbolus calculator.
SmartAdjust receives a CGM value and trend, then predicts where glucose levels will be an hour later. The system corrects every five minutes based on desired and customized glucose target.
The company anticipates the integrated technology to debut in the UK and Netherlands in phased launch in H1 2024.
“The addition of the Abbott FreeStyle Libre 2 Plus sensor to our CGM compatibility expands accessibility of Omnipod 5, which has been a priority for Insulet since the system launched in 2022,” said Patrick Crannell, Insulet’s senior VP and international GM. “We are excited to have achieved this key milestone, which allows us to bring Omnipod 5 and choice of CGM to more people with diabetes.”
The company released The OmniPod 5 AID integrated with the Dexcom G6 CGM in Germany in October 2023.